César Maldonado-García

César Maldonado-García

Auto-generated profile, based on publicly available information

César Maldonado-García

Centro Dermatológico “Dr. Ladislao de la Pascua”, Secretaria de Salud de la Ciudad de México, Mexico City 06780, Mexico

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 July 2020 in Mediators of Inflammation
Verified
Journal Article
Open access
PDF file
CACristina Aguilar-Flores
Cristina Aguilar-Flores
OCOCTAVIO CASTRO-ESCAMILLA
OCTAVIO CASTRO-ESCAMILLA
EOElizabeth M. Ortega-Rocha
Elizabeth M. Ortega-Rocha
CMCésar Maldonado-García
César Maldonado-García
FCFermín Jurado-Santa Cruz
Fermín Jurado-Santa Cruz
LBLaura Bonifaz
Laura Bonifaz
Psoriasis is an inflammatory autoimmune disease characterized by cutaneous lesions in plaques. It has been proposed that the immune response has a key role in the disease progression. Particularly, the Th17 cells through IL-17 can contribute to maintain the inflammatory process. The pathogenic Th17 phenotype has been described in human diseases and associated with high severity in inflammatory experimental models. However, it is not clear if the pathogenic phenotype could be present in the skin and peripheral blood as well as its possible association to severity in psoriasis. In the lesional skin, we found high infiltration of Th17 cells and the pathogenic phenotype, finding a correlation between the frequency of Th17 cells and the Psoriasis Area and Severity Index (PASI) score. In peripheral blood, we observed a pool of Th17 lymphocytes with potential to acquire pathogenic features. Interestingly, the percentage of pathogenic Th17 cells (CD4+ RORγt+ IFN-γ+) correlates with disease severity. Moreover, we distinguished three groups of patients based on their IL-17/IFN-γ production by Th17 lymphocytes, which seems to be related with a dynamic or stable potential to express these cytokines. Remarkably, we evaluated the cytokine production by Th17 cells as an immunological marker for the adequate selection of biologic therapy. We found that patients analyzed by this immunological approach and treated with antibodies against IL-17 and TNFα showed great improvement depicted by reduction in PASI and Dermatology Life Quality Index (DLQI) score as well as the percentage of Body Surface Area (BSA). Altogether, our results highlight the importance of the assessment of the pathogenic phenotype in Th17 cells as an immune personalized analysis with the potential to support the therapy choice in the clinical practice.

10 April 2017 in Advances in Therapy
Verified
Journal Article
Open access
PDF file
SASandra Adsit
Sandra Adsit
EZEnrique Rivas Zaldivar
Enrique Rivas Zaldivar
HSHoward Sofen
Howard Sofen
IDIgnacio Dei-Cas
Ignacio Dei-Cas
CMCésar Maldonado-García
César Maldonado-García
AGAdriana Guana
Adriana Guana
Introduction There is little evidence available on the efficacy and safety of biologic therapies for the treatment of psoriasis in Hispanic patients. Secukinumab is demonstrated to be highly effective for clearing psoriasis. The aim of this study was to compare the efficacy and safety of secukinumab in Hispanic and non-Hispanic patients. Methods Data were pooled from four phase 3 studies of secukinumab in patients with moderate-to-severe plaque psoriasis. Patients who self-identified as Hispanic were included in the Hispanic subgroup. Results Efficacy responses (Psoriasis Area and Severity Index [PASI] 75/90/100 and Investigator’s Global Assessment 2011 modified version 0/1) for secukinumab 300 mg were greater than for etanercept at week 12 in the Hispanic and non-Hispanic patient subgroups. At week 12 with secukinumab 300 mg, PASI 90/100 responses were achieved by 70.6%/35.9% of Hispanic patients and 58.0%/28.1% of non-Hispanic patients. At week 12 with secukinumab 150 mg, PASI 90/100 responses were achieved by 59.5%/25.1% of Hispanic patients and 41.2%/13.4% of non-Hispanic patients. In both subgroups, peak efficacy responses with secukinumab were observed at week 16 and were maintained to week 52. Conclusions Secukinumab is highly effective for clearing psoriasis in both Hispanic and non-Hispanic patients. Funding Novartis Pharmaceutical Corporation.